Drug-Induced Xerostomia: Medications, Mechanisms, and Dental Consequences

Core Review

Xerostomia vs. Hyposalivation

Xerostomia: The SUBJECTIVE sensation (complaint) of oral dryness. The patient FEELS dry.

Hyposalivation: OBJECTIVELY measured reduction in salivary flow. Unstimulated whole salivary flow rate <0.1-0.2 mL/min or stimulated flow rate <0.5-0.7 mL/min.

The two are related but not identical: a patient can report xerostomia with normal salivary flow (e.g., altered oral sensation, psychological factors), and a patient can have measurable hyposalivation without reporting dryness (particularly with gradual onset, where the patient adapts). However, in clinical practice, xerostomia and hyposalivation usually coexist.

Medication-Induced Xerostomia: The Most Common Cause

Medications are the MOST COMMON cause of xerostomia in the general population, particularly in older adults (due to polypharmacy, not aging per se — healthy aging does NOT significantly reduce salivary flow).

The primary mechanism is ANTICHOLINERGIC (ANTIMUSCARINIC) ACTIVITY — blockade of M3 muscarinic receptors on salivary acinar cells → reduced secretion of watery, serous saliva.

Medication classes causing xerostomia, organized by mechanism:

1. Drugs with Direct Anticholinergic Activity (M3 Receptor Blockade)

These are the most potent xerostomic agents. Many are prescribed specifically for their anticholinergic effects:

• Anticholinergics/antimuscarinics (therapeutic): Oxybutynin, tolterodine, solifenacin (overactive bladder); scopolamine (motion sickness); atropine; glycopyrrolate
• Antihistamines (1st generation — sedating): Diphenhydramine (Benadryl), chlorpheniramine, hydroxyzine, doxylamine. These cross the blood-brain barrier and have strong anticholinergic effects. 2nd generation antihistamines (loratadine, cetirizine, fexofenadine) are less anticholinergic and cause less xerostomia.
• Antipsychotics (typical and atypical): Phenothiazines (chlorpromazine), butyrophenones (haloperidol), olanzapine, quetiapine, clozapine
• Tricyclic antidepressants (TCAs): Amitriptyline, nortriptyline, imipramine, doxepin. Among the most anticholinergic antidepressants.
• Anti-Parkinson drugs: Benztropine, trihexyphenidyl

2. Drugs with Indirect or Mild Anticholinergic Effects

• SSRIs (selective serotonin reuptake inhibitors): Fluoxetine, sertraline, paroxetine, citalopram, escitalopram. Less anticholinergic than TCAs but still commonly cause xerostomia (mechanism unclear — may involve altered central perception or mild peripheral effects).
• SNRIs: Venlafaxine, duloxetine
• Benzodiazepines: Diazepam, lorazepam, alprazolam

3. Drugs Causing Xerostomia Through Non-Anticholinergic Mechanisms

• Sympathomimetics: Decongestants (pseudoephedrine), ADHD medications (methylphenidate, amphetamines). Reduce salivary flow via alpha-adrenergic vasoconstriction and/or central effects.
• Antihypertensives:
  • Central alpha-2 agonists (clonidine, methyldopa): Centrally mediated reduction in salivary flow — very prominent xerostomia
  • Diuretics: Dehydration, volume depletion → reduced salivary flow
  • Beta blockers (propranolol): Possible mild xerostomia
• Opioids: Dry mouth is common
• Proton pump inhibitors (omeprazole, pantoprazole): Dry mouth reported
• Chemotherapy agents: Direct damage to salivary gland parenchyma → hyposalivation (often temporary)
• Radiation therapy (head and neck): NOT a medication, but the most profound cause of xerostomia. Direct radiation damage to salivary glands → permanent fibrosis and destruction of acinar cells → severe, irreversible hyposalivation. Threshold: ~20-30 Gy causes measurable reduction; >60 Gy causes near-complete, permanent loss.

The Clinical Cascade of Xerostomia

Chronic xerostomia is NOT simply an annoyance — it has serious oral health consequences:

1. Loss of salivary protective functions:
   • Decreased antimicrobial activity (reduced sIgA, lysozyme, lactoferrin, peroxidase)
   • Decreased buffering capacity (reduced bicarbonate) → prolonged oral pH drops after meals
   • Decreased clearance of sugars and food debris
   • Decreased lubrication → mucosal fragility

1. Rampant dental caries:
   • Increased caries risk, especially CERVICAL (root surface) caries and recurrent caries around existing restorations
   • Caries at sites typically resistant to decay: cusp tips, incisal edges, smooth surfaces
   • Radiation caries: particularly aggressive, rapidly progressive decay in radiation patients

1. Oral candidiasis:
   • Increased susceptibility to pseudomembranous, erythematous, and angular cheilitis forms
   • Denture stomatitis (especially with continuous denture wear)

1. Mucosal changes:
   • Dry, atrophic, friable oral mucosa
   • Fissured, depapillated tongue
   • Traumatic ulceration (loss of lubrication and tissue protection)

1. Functional difficulties:
   • Dysphagia (difficulty swallowing — dry food, pills)
   • Dysphonia (voice changes, hoarseness)
   • Difficulty speaking for extended periods
   • Difficulty wearing dentures (loss of saliva as a "lubricant/seal")
   • Altered taste (dysgeusia)

1. Burning mouth syndrome:
   • Oral burning sensation, often without visible mucosal changes
   • May be multifactorial (xerostomia, candidiasis, nutritional deficiencies, neuropathy)

Xerostomia Assessment

History:

• When did the dry mouth start?
• Is it constant or intermittent?
• Does it affect eating, speaking, swallowing?
• Do you need to sip water to swallow dry foods ("cracker sign")?
• Do you wake up at night needing water?
• Complete medication review — including OTC medications, supplements, and herbal remedies (many have anticholinergic effects)

Clinical examination:

• Dry, atrophic mucosa
• Lips: dry, cracked, angular cheilitis
• Tongue: fissured, depapillated, coated
• Pooled saliva in floor of mouth: absent or minimal
• Saliva expressibility from major ducts: reduced or absent
• Mirror sticks to mucosa (tongue depressor sign)
• Cervical/root caries, recurrent decay
• Candidiasis (erythematous, pseudomembranous)

Objective assessment:

• Unstimulated whole salivary flow rate: Patient spits into collection tube for 5-15 minutes. Rate <0.1-0.2 mL/min = hyposalivation.
• Stimulated whole salivary flow rate: Same test with chewing stimulation (paraffin, gum). Rate <0.5-0.7 mL/min = hyposalivation.

Management of Medication-Induced Xerostomia

1. Identify and modify medications (if possible):

• Review ALL medications (prescription, OTC, supplements) for anticholinergic burden
• Consider: Can the xerostomic drug be substituted for a less xerostomic alternative? (e.g., oxybutynin → mirabegron for overactive bladder; amitriptyline → bupropion or mirtazapine for depression; diphenhydramine → loratadine/cetirizine for allergies)
• Consult with the prescribing physician
• IMPORTANT: Never advise a patient to discontinue a prescribed medication independently
• If the drug cannot be changed, focus on symptomatic management

2. Saliva stimulation (sialagogues):

• Sugar-free gum, sugar-free lozenges/candies: Chewing stimulates salivary flow through masticatory and gustatory pathways
• Xylitol-containing products: Xylitol is non-cariogenic and may have anti-caries effects
• Pilocarpine (Salagen): Cholinergic (muscarinic) agonist. Stimulates salivary secretion. Effectiveness depends on residual functional salivary gland tissue (ineffective if glands are completely fibrosed from radiation). Side effects: sweating, flushing, bradycardia, GI upset, urinary frequency. Contraindicated in uncontrolled asthma, narrow-angle glaucoma, acute iritis.
• Cevimeline (Evoxac): Muscarinic agonist with higher affinity for M3 receptors (more selective for salivary and lacrimal glands vs. pilocarpine). Side effects similar to pilocarpine.

3. Saliva substitutes (palliative):

• Artificial saliva products: Carboxymethylcellulose-based, mucin-based, or glycerin-based
• Available as sprays, rinses, gels, lozenges
• Provide temporary relief; do NOT stimulate natural saliva
• Best used at night or when eating is not anticipated

4. Caries prevention — CRITICAL:

• Optimize oral hygiene: Brush 2-3x/day with fluoride toothpaste, floss daily
• Prescription fluoride: 5,000 ppm fluoride toothpaste (Prevident 5000), or 0.4% stannous fluoride gel
• Fluoride varnish applications: Every 3-6 months (professional application)
• Chlorhexidine rinse: May be considered for high caries risk patients, though primary role is antimicrobial
• Dietary counseling: Reduce frequency of sugar intake, avoid sugary beverages, sip water instead
• Neutral pH water as frequent sips (not acidic beverages, not sugary drinks)

5. Candidiasis prevention and management:

• Assess for candidiasis at every visit
• Antifungal therapy if candidiasis present (topical first-line: nystatin, clotrimazole; systemic for severe/refractory cases: fluconazole)
• Denture hygiene: remove dentures at night, soak in cleaning solution

6. Symptom management:

• Frequent sips of water (carry water bottle)
• Humidifier at night
• Avoid alcohol-containing mouthwashes (drying)
• Avoid caffeine, alcohol, and tobacco (all drying/irritating)
• Use lip balm/moisturizer for dry lips

Polypharmacy and Anticholinergic Burden

Older adults often take multiple medications, each with mild anticholinergic effects — the cumulative anticholinergic burden can become significant. The Anticholinergic Risk Scale (ARS) and Anticholinergic Drug Scale (ADS) are tools used to quantify this burden. The dental hygienist should recognize that polypharmacy in the elderly is a major contributor to xerostomia, even when no single drug is strongly anticholinergic.

Sjögren's Syndrome: The Prototype Autoimmune Xerostomia

While medications are the most common cause, Sjögren's syndrome is the most important non-medication cause of xerostomia that the NBDHE tests:

• Autoimmune destruction of salivary and lacrimal glands
• Primary: Xerostomia + keratoconjunctivitis sicca (dry eyes)
• Secondary: Above + another autoimmune disease (rheumatoid arthritis, SLE, scleroderma)
• 90% female, peak age 40-60
• Labial minor salivary gland biopsy: focal lymphocytic sialadenitis (focus score ≥1)
• Autoantibodies: Anti-Ro/SSA, Anti-La/SSB
• Management: symptomatic + pilocarpine/cevimeline + aggressive caries prevention

Clinical Application

The dental hygienist plays a central role in managing xerostomic patients: (1) identifying xerostomia through history and exam, (2) reviewing the medication list for xerostomic agents, (3) implementing aggressive caries prevention, (4) monitoring for candidiasis, (5) educating the patient about the relationship between their medications and oral dryness, and (6) communicating with the patient's physician about possible drug substitutions when appropriate.

Common Traps

• Thinking xerostomia is a normal part of aging — it isn't; it's primarily medication-related
• Attributing xerostomia to one drug when the patient is on multiple mildly anticholinergic drugs (cumulative effect)
• Focusing on managing xerostomia symptoms while neglecting aggressive caries prevention
• Confusing ACE inhibitor cough with xerostomia — ask the right questions
• Thinking all antihistamines are equally xerostomic — 2nd generation (loratadine, cetirizine) are much less so